Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: Results of a prospective study

Bone Marrow Transplantation

Volumn 44, Issue 11, 2009, Pages 729-737

  Skert, C ^a   Damiani, D ^b   Michelutti, A ^b   Patriarca, F ^b   Arpinati, M ^c   Fili C ^a   Lucchi, P ^a   Malagola, M ^a   Bergonzi, C ^a   Roccaro, A ^a   Peli, A ^a   Ricotta, D ^a   Caimi, L ^a   Fanin, R ^b   Baccarani, M ^c   Russo, D ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Allo SCT; Chronic GVHD; Cytokines; Lymphocytes

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; FLUDARABINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MALE; MULTIPLE MYELOMA; MYELOFIBROSIS; NATURAL KILLER CELL; PATHOGENESIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; TH1 CELL; TH2 CELL;

ADULT; AGED; CHRONIC DISEASE; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 75049085550     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.80     Document Type: Article

References (43)

1. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125: 435-454.
2. Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program 2003, 350-371.
3. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998; 22: 873-881. (Pubitemid 28499360)
4. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
5. Zorn E. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 2006; 16: 150-159.
6. Shindo T, Ishikawa T, Fukunaga A, Hori T, Uchiyama T. Growth and differentiation advantages of CD4+OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2008; 14: 268-281.
7. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002; 2: 37-45.
8. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252.
9. Fimiani M, De Aloe G, Cuccia A. Chronic graft versus host disease and skin. J Eur Acad Dermatol Venerol 2003; 17: 512-517.
10. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versushost disease. Bone Marrow Transplant 1994; 13: 745-751. (Pubitemid 24195790)
11. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma 1995; 17: 169-173.
12. Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis factor á and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 706-712.
13. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002; 168: 3088-3098.
14. Bell SA, Faust H, Mittermüller J, Kolb HJ, Meurer M. Specificity of anti-nuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Haematol 1996; 134: 848-854.
15. Skert C, Patriarca F, Sperotto A, Cerno M, Filì C, Zaja F et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006; 91: 258-261.
16. Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, Mestroni R et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006; 34: 389-396.
17. Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med 1994; 120: 993-998.
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man: a long term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
20. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
21. Jolliffe IT. Principal component analysis. Springer 2002.
22. Kachigan SK. Statistical analysis. Radius Press: New York, 1986.
23. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998; 15: 863-871.
24. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller FC, Hakim FT et al. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4+effector memory cells relative to central memory cells. Blood 2004; 103: 3986-3988.
25. Kotani A, Ishikawa T, Matsumura Y, Ichinohe T, Ohno H, Hori T et al. Correlation of peripheral blood OX40+ (CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3162-3164.
26. Meignin V, de Latour RP, Zuber J, Règnault A, Mounier N, Lemaitre F et al. Numbers of FOXp3-expressing CD4+CD25 high T cells do not correlate with the establishment of longterm tolerance after allogeneic stem cell transplantation. Exp Hematol 2005; 33: 894-900.
27. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25 high regulatory T cells. Blood 2004; 103: 2410-2416.
28. Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 2003; 8: 19-26.
29. Shenoy S, Mohanakumar T, Todd G, Westhoff W, Dunnigan K, Adkins DR et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant 1999; 23: 335-346.
30. Pazmany L. Do NK cells regulate human autoimmunity? Cytokine 2005; 32: 76-80.
31. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: l'union fait la force'. Blood 2005; 106: 2252-2258.
32. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
33. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor-and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005; 105: 2227-2234.
34. Wilson JL, Heffler LC, Charo J, Scheynius A, Bejarano MT, Ljunggren HG. Targeting of human dendritic cells by autologous NK cells. J Immunol 1999; 163: 6365-6370.
35. Salazar-Fontana LI, Bierer BE. T-lymphocyte coactivator molecules. Curr Opin Hematol 2001; 8: 5-11.
36. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005; 80: 555-563.
37. Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol 1998; 10: 669-676.
38. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft versus-hostdisease. Blood 2005; 106: 2903-2911.
39. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol 2003; 24: 36-43.
40. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun 2003; 20: 281-285.
41. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998; 160: 3188-3193.
42. Hill N, Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol 2002; 14: 791-797.
43. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008; 111: 3276-3285.